| 000 | 01072 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250514070648.0 | ||
| 264 | 0 | _c20030623 | |
| 008 | 200306s 0 0 eng d | ||
| 022 | _a1756-1833 | ||
| 024 | 7 |
_a10.1136/bmj.326.7400.1212-a _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChadwick, David | |
| 245 | 0 | 0 |
_aShared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cMay 2003 |
||
| 300 |
_a1212-3 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAzathioprine _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xeconomics |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aRisk Sharing, Financial |
| 700 | 1 | _aGray, Richard | |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 326 _gno. 7400 _gp. 1212-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.326.7400.1212-a _zAvailable from publisher's website |
| 999 |
_c12561746 _d12561746 |
||